Reading the tape
NASDAQ: CLNN
Clene Inc.
Healthcare · Biotechnology
Market Cap
$80.90M
52w High
$13.50
52w Low
$2.28
P/E
-3.05
Volume
21.95M
Outstanding Shares
10.00M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 178.01%Revenue (TTM): -41.52%FCF (TTM): 12.91%
What changed
The stock rose 178.01% over the last year. Revenue declined 41.52% over the trailing twelve months. Operating margin moved from -9,676.32% to -11,541.5%. Free cash flow grew 12.91% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -11,541.5%. A decisive move in revenue — currently down 41.52% — would be the clearest signal to resolve the ambiguity.
Company profile
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CEORobert Etherington
SectorHealthcare
IndustryBiotechnology
Employees75
IPO dateOct 18, 2018
Valuation
Forward P/E—
EV/EBITDA-3.44
Enterprise value$74.36M
Stock splits
Jul 11, 2024↓ Reverse
Every 20 shares became 1
Profitability & growth
Revenue growth-15.38%
Gross margin78.5%▼1.30%vs FY2024
Operating margin-11,541.5%▼19.28%vs FY2024
ROE148.78%▼66.56%vs FY2024
Analyst consensus
RatingBuy
Target price$50.00▲518.05%
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.62 · Revenue est $50.75K
View